[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556529":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":22,"centralContacts":26,"locations":10,"responsibleParty":32,"collaborators":34,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":10,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":10,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":10,"overallStatus":60,"whyStopped":10,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":10},{"fullName":5,"class":6},"University of Colorado, Denver","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Usual Care",null,"Control group to enable tracking of temporal changes in prescribing. Providers will not see any alert.",{"label":13,"type":10,"description":14,"interventionNames":15},"CDS Notification","Providers will see a clinical decision support tool within the electronic health record when treating a patient at risk for opioid use disorder to encourage the provider to use a clinical care pathway to assess for opioid use disorder and when applicable, treat opioid use disorder with buprenorphine. Smart text will also be available in the electronic health record so that the provider can easily document screening and treatment discussions with the patient.",[16],"Other: Medications for Opioid Use Disorder Pathway Clinical Decision Support (CDS)",[18],{"type":6,"name":19,"description":20,"armGroupLabels":21,"otherNames":10},"Medications for Opioid Use Disorder Pathway Clinical Decision Support (CDS)","Clinical decision support (CDS) in the form of an electronic health record (EHR)-integrated, provider-facing notification suggesting (a) the patient may be at risk for opioid use disorder and could benefit from screening, (b) patients with opioid use disorder would benefit from treatment with buprenorphine and (c) utilization of a clinical care pathway to help treat patients with opioid use disorder with buprenorphine as suggested by the Center for Disease Control and Prevention (CDC) guidelines.",[13],[23],{"name":24,"affiliation":5,"role":25},"Jason Hoppe, DO","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"Heather Tolle, PhD","CONTACT","303-724-9924","heather.tolle@cuanschutz.edu",{"type":33,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[35,38],{"name":36,"class":37},"National Institutes of Health (NIH)","NIH",{"name":39,"class":37},"National Institute on Drug Abuse (NIDA)","100556529","clinical-decision-support-to-increase-use-of-medications-for-opioid-use-disorder-100556529",false,"NCT06526286","Clinical Decision Support to Increase Use of Medications for Opioid Use Disorder","Inclusion Criteria:\n\n* Primary care encounter AND\n* Current opioid prescription (not buprenorphine) and Active opioid medications over the last 90 days OR\n* Documented as on local Pain Registry \"Does the patient fit the criteria to be included on the Pain Registry?\" OR\n* Has active problem list diagnosis of long-term (current) use of opiate analgesic OR\n* Is taking \\>=90 morphine milligram equivalents (MME) per day OR\n* Prior positive toxicology screen for illicit drugs OR\n* Diagnosis of opioid use disorder\n\nExclusion Criteria:\n\n* Active cancer diagnosis in the last 1 year\n* Hospice care\u002Fpalliative care order\n* Sickle cell disease diagnosis",true,"ALL","12 Years","89 Years",{"count":51,"type":52},200000,"ESTIMATED","OBSERVATIONAL","The objective of this study is to evaluate the impact of clinical decision support (CDS) in the form of an alert to identify patients who may be at risk of opioid use disorder (OUD) and a clinical care pathway helping providers treating patients with opioid use disorder. The pathway provides health care providers with information and suggestions for screening and treatment of opioid use disorder, including treatment with medications. The 2022 Centers for Disease Control and Prevention (CDC) clinical practice guideline for prescribing opioids for pain recommends providers asses for and treat opioid use disorder using approved medications for opioid use disorder (MOUD). This project will randomize primary care providers at the clinic level to a control arm or intervention arm. The control arm will have access to the clinical care pathway, but will not be reminded to utilize the pathway when treating a patient with opioid use disorder. The intervention arm will receive a reminder nudge about the pathway. Buprenorphine (a medication used to treat opioid use disorder) prescribing behavior of providers and outcomes of patients will be examined based on medical records data collected during routine care. The study period will be approximately 18 months.",[56,57,58,59],"Medication Abuse","Harm Reduction","Opioid Use Disorder","Supportive Care","NOT_YET_RECRUITING","2026-04-20",{"date":63,"type":64},"2026-04-23","ACTUAL",{"date":66,"type":52},"2026-06",{"date":68,"type":52},"2027-05",{"name":5,"class":6}]